Andrew Mather

Title: The Innovations of Andrew Mather

Introduction

Andrew Mather is a notable inventor based in Loughborough, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as muscarinic receptor antagonists. With a total of 2 patents to his name, Mather's work is recognized for its potential therapeutic applications.

Latest Patents

Mather's latest patents include innovative compounds that have promising uses in therapy. One of his patents focuses on quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid, which are designed as muscarinic receptor antagonists. This invention provides compounds of formula (I) wherein R is a group of formula (II) or (IIIa) or (IIIb), along with a detailed process for their preparation, pharmaceutical compositions containing them, and their therapeutic uses. Another patent involves substituted 1-cyanoethylheterocyclylcarboxamide compounds, which also includes a process for their preparation and pharmaceutical applications.

Career Highlights

Andrew Mather is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative drug development, contributing to advancements in medical science.

Collaborations

Mather has collaborated with several professionals in his field, including Rhonan Lee Ford and Antonio Mete. These collaborations have enhanced the research and development of his patented compounds.

Conclusion

Andrew Mather's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical therapies. His patents reflect a deep understanding of chemical compounds and their potential applications in healthcare.